Some time ago, "I am not a drug god" brought the public's eyes to the innovative medicine industry, but the Chinese pharmaceutical market presented in the film has become a thing of the past. In recent years, in the field of new drug research and development, China has continuously introduced relevant incentive policies, which also makes the current pharmaceutical market growth rate in China exceed the global average.
Of course, as early as in the past few decades, various medical innovation companies have been constantly exploring and conquering new targets. For this reason, the average time for launching new drugs worldwide is continuing to increase, and the success rate of new drug research and development is also decreasing.
In this regard, Dr. Shen Wang, the founder of Weiwei Biotech, told Yiou Health that in this global context, China's innovative pharmaceutical market still maintains a relatively high growth rate, mainly due to the “debt†of the past innovative drugs in China. many. He believes that the policy dividend for China's innovative drug market will continue for 5 to 10 years.
"立军心" begins with the project
In the past, in Shen Wang's view, from the perspective of market and policy, the development of the domestic innovative pharmaceutical industry has not been clear, and industry norms have not yet been formed. In 2016, when Shen Wang discovered that the domestic innovative drug policy was gradually opening up, he decided to return from the United States to create a vitamin in the country.
In the early days of the establishment of Wei Wei, Shen Wang decided that the development of the team should start with the "center of the army." In his view, Wei Weisheng should first think clearly about how to establish a project, and to carry out differentiated competition and solve clinical problems is the two key links he believes to be a project.
1. Bypassing the competition for the white-hot tumor market
Shen Wang told Yiou Health that 90% of the companies engaged in innovative medicines in the industry are concentrated in the field of cancer, but there are few concerns in the field of ophthalmology, dermatology and other chronic diseases. Of course, it is not difficult to understand that the disease in the field of cancer is due to its harmfulness, whether it is the patient's willingness to pay, or the academic prospects of the industry is indeed enough for most pharmaceutical innovation companies to plung into the track.
However, due to the complexity of tumor diseases, high investment is required in the early stage of research and development, and the process needs to be constantly trial and error, and the team's return period is naturally lengthened. Shen Wang believes that these are not conducive to "establishing a military heart" for a young and innovative pharmaceutical company.
In addition, in Shen Wang's view, the field of innovative drugs is often difficult. In the field of tumors, after the discovery of new targets such as PD-1 and PD-L1, innovative drug companies in the field of cancer will find it harder to find new targets. Not only that, Shen Wang told the billion euros of health, currently targeting the same target in the field of cancer, there are more than 40 innovative pharmaceutical companies in the world to study it, the track competition will become hot in the future.
In contrast, in the ophthalmology field where Wei Wei focuses, the incidence of dry eye syndrome has increased in recent years due to factors such as eye hygiene, environmental pollution, and population aging. According to epidemiological surveys, the incidence of dry eye in developed countries is about 15% to 16%, while the incidence of dry eye in China is 21%.
Shen Wang believes that the huge domestic clinical demand in this field has not been met. In addition to the artificial tear products with limited efficacy, there are no targeted therapeutic drugs for dry eye in the Chinese market. For this reason, Wei Weisheng began to overcome the treatment problems of dry eye syndrome.
2, from the side effects to solve clinical problems
In fact, in addition to the market competition in the field of ophthalmology and dermatology, which is focused on the company, in the view of Shen Wang, whether the clinical problem can be solved is the decisive factor in the establishment of the project.
At present, the vitamins are mainly focused on the topical application of ophthalmology and dermatological diseases. The topical medication is a commonly used treatment method in clinical practice, and has the advantages of high local drug concentration, good curative effect, convenient administration, and the like, and the medicine does not enter the blood mainly through application of molecular reagents and preparations.
Shen Wang told Yiou that the health is serious. In fact, most of the diseases in the fields of ophthalmology and dermatology are inseparable from the human immune system. Taking skin diseases as an example, the principle of disease is mainly caused by inflammation of human T cells after entering the surface of the skin. Shen Wang said that the treatment plan for a serious eczema patient cannot be relied on only on the surface, but through systemic administration. Way to treat.
Although the efficacy of topical medication is generally good, adverse reactions also occur from time to time because the drug contains strong hormones. Taking ophthalmic diseases as an example, Shen Wang said that on the one hand, topical medications for the eyes need to have good water solubility; on the other hand, different strategies need to be adopted in reagent development to make the compounds more susceptible to degradation when entering the bloodstream. This reduces the risk of side effects of the drug.
At present, V. Bio has independently developed PDE4 inhibitors and LFA1 inhibitors for the treatment of eczema and dry eye. In addition, its self-developed Best in Class dry eye syndrome drug has also entered the IND (Clinical Trial Application) preparation phase, and is expected to start clinical trials next year.
Tactics after the bonus disappears
Although Shen Wang believes that the domestic policy dividend will remain for 5 to 10 years, when the policy dividend gradually disappears, and what kind of strategy should enterprises use to enhance their core competitiveness, Shen Wang also has its own judgment. In the end, he will "take roots in chronic diseases and develop multiple product pipelines" as the tactics of Wei Wei's five years later.
From the beginning of the establishment of Wei Wei, Shen Wang led the team into the field of chronic diseases, which was mainly due to his prediction of the future development of chronic diseases in China. He believes that in the current situation of chronic disease patients in China is large enough, the possibility of its increase is correspondingly larger. In this regard, the "Health Management Blue Book: China Health Management and Health Industry Development Report (2018)" data also shows that the number of chronic diseases in China is about 300 million, of which the chronic disease burden of people under 65 years old accounts for 50%.
In addition, how to ensure the sustainable research and development capabilities of Weiwei Biological is also a question that Shenwang has been thinking about. After thinking, he told Yiou that the health of Weiyi is to continue to deepen the field of ophthalmology and dermatology, and gradually develop multiple product pipelines. In this regard, Shen Wang said that the future treatment of patients with vitamins will no longer be limited to topical medication. After the "military heart" is stabilized, Weiwei Biotech will develop difficult product pipelines in time to develop colleagues in various product development pipelines.
According to the health of 100 million euros, Weiwei Biotech announced on July 13 this year that it completed a 50-billion-yuan B-round financing. Shen Wang said that this financing will be mainly used to support the clinical practice of the innovative drug project of Weiwei Biological Dry Eye Syndrome. Phase I trials, as well as the development of other product pipelines.
In addition, the Virgin Bio team will be expanded from 20 to 30 by the end of the year. In terms of product development, Shen Wang said that in the future, Wei Wei may enter the OTC to occupy the domestic market with a good winning strategy.
Tetanus Shot,Tetanus Vaccine,Hepatitis B Injection,Hep B Vaccine
FOSHAN PHARMA CO., LTD. , https://www.fspharmaapi.com